0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SLAMF7

SLAMF7

SLAMF7 Molecule Information

Name:SLAM family member 7
Target Synonym:Novel Ly9?CS1?CD_antigen=CD319?Membrane protein FOAP-12?CRACC?SLAMF7?Protein 19A?SLAM family member 7?CD2 subset 1?CD2-like receptor-activating cytotoxic cells
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

SLAMF7 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
SL7-HF2H7 Human FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-HF2H7-structure
SL7-HF2H7-sds
SL7-R52H7 Rhesus macaque Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-R52H7-structure
SL7-R52H7-sds
SL7-M5252 Mouse Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin
SL7-M5252-structure
SL7-M5252-sds
SL7-H82E0 Human Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag
SL7-H82E0-structure
SL7-H82E0-sds
SL7-H82E0-elisa_1
SL7-H5256 Human Human SLAMF7 / CRACC / CD319 Protein, Fc Tag
SL7-H5256-structure
SL7-H5256-sds
SL7-H5256-elisa_1
SL7-H5225 Human Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-H5225-structure
SL7-H5225-sds
SL7-H5225-elisa_1

SLAMF7 Molecule Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

SLAMF7 Molecule Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 References

SLAMF7 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elotuzumab HuLuc-63; BMS-901608; PDL-063 ,HuLuc63,BMS901608 Approved Abbvie, Bristol-Myers Squibb EMPLICITI fda Multiple myeloma (MM) BRISTOL MYERS SQUIBB 2015-11-30 Multiple myeloma (MM) Details

SLAMF7 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
UCART-CS1 UCART-CS1; UCART-38 Phase Ⅰ Cellectis, M.D. Anderson Cancer Center Multiple myeloma (MM) Details
Azintuxizumab vedotin ABBV-838 Phase Ⅰ Abbvie Multiple myeloma (MM) Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) Phase Not Specified Wuhan Bio-Raid Biotechnology, Tongji Hospital hematological malignancies Details

This web search service is supported by Google Inc.

totop